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Serum interleukin-8 (IL-8) and interferon-alpha (IFN-α) levels have been estimated from a total of 88 individuals of which 19
were disease-free healthy individuals, and 69 were patients with thyroid diseases: goitre (N = 21), autoimmune diseases (N = 16),
and carcinomas (N = 32). Both IL-8 and IFN-α were signiﬁcantly higher in all the patients as compared to healthy individuals.
Serum IL-8 levels showed signiﬁcant positive correlation with disease stage in thyroid cancer patients. Higher serum IL-8 levels
were associated with advanced disease stage while no signiﬁcant correlation was observed between serum IFN-α levels and any
of the clinicopathological parameters. IL-8 and IFN-α signiﬁcantly correlated with each other in anaplastic carcinoma patients.
Finally concluding, monitoring the serum IL-8 and IFN-α levels can help diﬀerentiate patients with thyroid diseases from healthy
individuals, and IL-8 seems to have a role in the pathogenesis of thyroid diseases and may represent a target for innovative
diagnostic and therapeutic strategies.
1.Introduction
Although thyroid problems are among the most common
medical conditions, because their symptoms often appear
gradually, they are commonly misdiagnosed. The three most
common thyroid problems are the underactive thyroid, the
overactive thyroid, and thyroid nodules [1]. Based on these
problems, the disorders of the thyroid gland include: goitre,
autoimmune thyroid diseases, as well as thyroid carcinoma.
Thyroid cancer is the fastest growing and most common
cancer of the total endocrine malignancies, accounting for
94.5% of the total new endocrine cancers and 65.9% of the
deaths due to endocrine cancers. It is the endocrine tumor
that bears the highest incidence with 33 550 new cases per
year in the US [2]. The vast majority of patients with thyroid
diseases are curable using present treatment modalities.
However, accumulating evidences indicate that follicular
cell-derived thyroid cancer constitutes a biological contin-
uum progressing from the highly curable well-diﬀerentiated
thyroid cancer to the universally fatal anaplastic thyroid
cancer [3, 4]. An association between thyroid cancer and
a history of several benign diseases has been observed in
most studies [5, 6]. However, the molecular mechanisms
underlying thyroid cancer progression remain ill-deﬁned. So
it is important to decipher these mechanisms, since poorly
diﬀerentiated and anaplastic carcinomas account for the
majority of thyroid cancer-related deaths.
Moreover, accumulated epidemiologic studies support
that chronic inﬂammatory diseases are frequently associated
with increased risk of cancers [7–9]. It is estimated that2 Journal of Thyroid Research
underlying infections and inﬂammatory responses are linked
to 15–20% of all deaths from cancer worldwide [7]. There
are many triggers of chronic inﬂammation that increase the
risk of developing cancer. Such triggers include microbial
infections, autoimmune diseases, and inﬂammatory condi-
tions of unknown origin. The hallmarks of cancer-related
inﬂammation include the presence of inﬂammatory cells
and inﬂammatory mediators (e.g., chemokines, cytokines,
and prostaglandins) in tumor tissues, tissue remodeling and
angiogenesis similar to that seen in chronic inﬂammatory
responses, and tissue repair. Indeed, inﬂammatory cells
and mediators are present in the microenvironment of
most, if not all, tumors, irrespective of the trigger for
development [10]. Cytokine shedding by tumor cells into
the local microenvironment is an important modulator
of tumorigenesis [11]. Thus, the relationship between the
immune system and cancer is complex, and cytokines,
chemokines, and growth factors in the tumor environment
play a key role in this interaction [12].
Cytokines are a category of signaling proteins and
glycoproteins that, like hormones and neurotransmitters, are
used extensively in cellular communication, which mediate
and regulate immunity, inﬂammation, and hematopoiesis.
Thus,cytokinesareagroupofpolypeptidesproducedmainly
by inﬂammatory cells, but also by nonimmune cells, and
have a key role in triggering and coordinating inﬂammatory
and immune reactions [13].
However, the relationships between cytokines and cancer
are multiple and bidirectional. On one hand, cytokines
may directly inﬂuence carcinogenesis and metastasis by
modifying the tumor phenotype while, on the other hand
during tumor progression, modiﬁcations of the cytokine
expression in the tumor environment may be induced by
the tumor cells [14]. Thus, a better understanding of the
basis of molecular talk between tumor cells and the immune
system would be helpful in developing immunotherapeutic
approaches.
Interleukin-8 (IL-8) is one of the best-characterized
members of C-X-C subfamily of the chemotactic cytokines
[15, 16]. It is a proinﬂammatory cytokine produced by
macrophages and other cell types such as epithelial cells.
As it serves as a chemical signal that attracts neutrophils
at the site of inﬂammation, it is also called “neutrophil
chemotactic factor”. Interleukin (IL)-8 is produced by a
wide variety of normal cells as well as tumor cell and its
principal role is in the initiation and ampliﬁcation of acute
inﬂammatory reactions. IL-8 has also been implicated in
chronic inﬂammatory processes and diseases with a chronic
inﬂammatory component such as cancer. IL-8 has been
shown to contribute to human cancer progression through
its potential functions as a mitogenic, angiogenic, and mito-
genic factor [17, 18]. Recent studies have demonstrated that
IL-8regulatestumorcellgrowthandmetastasisinmelanoma
[19], carcinoma of breast [20], stomach [21], pancreas [22],
and liver [22, 23]. Elevated serum level of IL-8 was found
to be a prognostic marker in soft tissue sarcoma [24], B-cell
chronic lymphocytic leukemia [25], primary gastrointestinal
non-Hodgkin’s lymphoma [26], and malignant melanoma
[27].
So, understanding the mechanisms of IL-8 expression
can be helpful in designing potential therapeutic strategies of
targeting IL-8 to control tumor growth and metastasis. On
the other hand, according to current data, endocrine system
is closely related to immune system, and interferons play an
important role in this relationship. Interferons can inhibit
cell proliferation or control apoptosis [28].
Interferon-alpha (IFN-α) is a small protein released by
macrophages, lymphocytes, and tissue cells infected with a
virus, it has pleiotropic properties and exerts a wide range
of immunomodulatory activities [29]. It is predominantly
characterized as an antiviral and antiproliferative agent
which stimulates both macrophages and natural killer cells
to elicit an antiviral response, and it is also active against
tumors. Besides, a very important property of IFN-α is its
ability to arrest the cell in the G1-G0 phase, which is what
determines static eﬀect of IFN-α on growth of many tumors
[28]. Moreover, IFN-α is a potent activator of monocytic
functions. But, since human monocytes are major producers
of neutrophil chemotactic cytokine: IL-8, we have been
tempted to study levels of both these cytokines (IL-8 and
IFN-α) in sera of patients with thyroid disorders by ELISA.
Moreover, it is much more convenient to quantitate serum
levels of these cytokines than to evaluate their expression in
tissue specimens as the former approach is noninvasive and
reproducible. Furthermore, it does not require tumor tissue
specimens.
So, the aim of this study was to explore the occurrence
of interleukin-8 and interferon-alpha in sera of patients
with various thyroid diseases (goiter, autoimmune disorders,
and thyroid carcinoma) and to correlate the results with
clinicopathological parameters in thyroid cancer patients.
2.MaterialsandMethods
Our study included a group of 88 individuals, out of which
69 were patients with thyroid disorders (goiter: N =
21, autoimmune thyroid diseases: N = 16, and thyroid
carcinoma: N = 32) and 19 were age-matched disease-
free healthy individuals (Table 1). The mean age of healthy
individuals included in the study was 30.57 years (range: 18–
56 years). Goiter occurred in patients at an earlier age (mean
age: 34.23 years, range: 18–58 years) while the occurrence of
autoimmune thyroid disease (mean age: 42.81 years, range:
26–61 years; P = .04) and thyroid carcinoma (mean age:
43.96 years, range: 18–78 years; P = .034) was found in
moreelderlypeople.ButasintheAmericanJointCommittee
on Cancer (AJCC) TNM staging system, the patients are
staged on the basis of their age (<45/≥45 years), we have also
groupedourpatientsintoayounger(<45years)andanolder
group (≥45 years) (Table 1).
Fasting blood samples were collected in the morning
from disease-free healthy individuals and patients with
thyroid diseases in vacuettes with gel for serum separation.
All patients with thyroid disorders were never previously
treated with chemotherapy, surgery, or radiotherapy at the
time of blood collection. Moreover, none of these patients
were ever before diagnosed with any other autoimmuneJournal of Thyroid Research 3
Table 1: Characterization of patients with thyroid diseases and healthy individuals.
Subjects N (%) Gender Age
Male Female <45 years ≥45 years
Healthy individuals 19 6 13 15 4
Total Patients 69 16 53 40 29
Goiter 21 (30.43) 3 18 14 7
Autoimmune diseases 16 (23.18) 4 12 9 7
Graves’ disease 12 (17.38) 4 8 7 5
Hashimoto’s disorder 4 (5.79) — 4 2 2
Thyroid carcinoma 32 (46.37) 9 23 17 15
Papillary 18 (26.07) 3 15 12 6
Follicular 7 (10.14) 2 5 2 5
Medullary 4 (5.79) 2 2 2 2
Anaplastic 3 (4.34) 2 1 1 2
disease, no one of them was taking immunosuppressive
or immunomodulant drugs. Prior to pretherapeutic blood
collection, written consent of the patients was taken.
Serums were separated from all blood samples after
centrifugation and were stored at −80◦C until analysis. IL-8
and IFN-α were determined from the serum samples using
commercially available enzyme immunoassay (EIA) kits
from Immunotech (A Beckman Coulter Company, France)
following the manufacturer’s instructions. The detailed
clinical and histopathological characteristics of all patients
were noted from the case ﬁles maintained at Gujarat Cancer
and Research Institute (Table 2).
2.1. Statistical Analysis. The results were presented as mean
± standard error of mean (M ± S.E.). Mann-Whitney U test
was performed to assess the diﬀerences in serum IL-8 and
IFN-α levels between healthy individuals and patients with
thyroid diseases. Receiver’s operating characteristic (ROC)
curveswerealsoconstructedtodeterminethediscriminating
eﬃcacy of IL-8 and IFN-α between healthy individuals and
patients with thyroid diseases. P values <.05 were considered
statistically signiﬁcant. Also, in thyroid cancer patients, the
association between IL-8 and IFN-α levels and clinicopatho-
logical parameters was analyzed by Mann-Whitney U test,
andthespearman’scorrelationwasusedtodescribeindepen-
dent relationship between serum IL-8 and IFN-α levels.
3. Results andDiscussion
Serum IL-8 and IFN-α levels were signiﬁcantly elevated
in all patients with thyroid disorders (goitre, autoimmune
thyroid disorders, and thyroid carcinoma) as compared to
healthy individuals. IL-8 and IFN-α levels in thyroid car-
cinoma patients with diﬀerent histopathological subgroups
and stages have also been compared to that of healthy
individuals.Statisticallysigniﬁcanthigherlevelsofboththese
cytokines were found in patients with papillary and follicular
carcinoma while, in medullary carcinoma patients, IFN-
α and, in anaplastic carcinoma patients, IL-8 levels were
found to be signiﬁcantly increased as compared to healthy
individuals. Early-stage thyroidcarcinoma patients exhibited
signiﬁcant higher levels of IFN-α, but not of IL-8, while IL-
8 and not IFN-α levels were found signiﬁcantly elevated in
advanced-stage thyroid carcinoma patients in comparison to
healthy individuals (Tables 3 and 4).
ROC curve (Figure 1(a)) indicates that both IL-8 and
IFN-α exhibited a good discriminatory eﬃcacy between
healthy individuals and total patients with thyroid diseases
(IL-8: AUC-0.756; IFN-α: AUC-0.795). Moreover, the ROC
curves for both the cytokines between healthy individuals
and individual groups of patients, that is, goiter, autoim-
mune disease, and thyroid cancer, revealed that both IL-8
as well as IFN-α showed good sensitivity and speciﬁcity to
discriminatebetweenhealthyindividualsandpatientshaving
diﬀerent thyroid diseases (goiter- IL-8: AUC-0.774, IFN-α:
AUC-0.797; autoimmune thyroid disease- IL-8: AUC-0.711,
IFN-α: AUC-0.755, and thyroid cancer- IL-8: AUC-0.767,
IFN-α: AUC-0.813) (Figures 1(b)–1(d)). Only IL-8 could
signiﬁcantly discriminate between early- and advanced-stage
thyroid cancer patients (Figure 1(e)).
Similar to the present study, Limkov et al. have demon-
strated statistically signiﬁcant diﬀerences in IL-8 levels
thyroid disease patients and reference normal group [30].
Bossowski and Urban and Siddiqi et al. have also observed
signiﬁcantly elevated levels of IL-8 in patients with Graves’
disease and nodular goiter as compared to the respective
healthy control groups [31, 32]. In contrast to these of
studies, Krassas and colleagues found that IL-8 levels were
not elevated in Graves’ disease, toxic nodular goiter and
Hashimoto’s thyroiditis [33]. A study by Lee et al. has
shown increased levels of cytokines including IL-8 and IL-
10 in patients who frequently developed euthyroid sick syn-
dromes followed by allogeneic bone marrow transplantation
[34]. Antonelli et al. observed increased CXCL10 levels in
autoimmune thyroiditis [35]. Also, they have demonstrated4 Journal of Thyroid Research
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(c) Healthy individuals and patients with autoimmune thyroid disease
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(d) Healthy individuals and thyroid cancer patients
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(e) Early stage and advanced stage thyroid carcinoma
Figure 1: ROC curves for IL-8 and IFN-α.
elevated circulating levels of CXCL10 and IFN-gamma in
patients with Graves’ disease, particularly in those with
Graves’ ophthalmopathy [36]. Increased IL-8 levels have also
been observed in patients with other malignancies. In their
study,Yi.Renetal.alsofoundthatthelevelofserumIL-8was
markedly elevated in most patients with HCC as compared
with healthy subjects [37]. In fact, elevated serum level of
IL-8 was found to be a prognostic marker in soft tissue
sarcoma [38], B-cell chronic lymphocytic leukemia [39],
primary gastrointestinal non-Hodgkin’s lymphoma [40],
and malignant melanoma [41]. So, high serum levels of both
the cytokines in thyroid carcinoma patients may be caused
by an excessive production in tumor cells and subsequent
release into the circulation.
The incidence of patients with thyroid diseases having
higher levels of IL-8 and IFN-α than those of healthy
individuals has been shown in Figures 2(a)–2(c).T h e
levels of IL-8 > 7.00ng/ml (maximum level of IL-8 in
healthy individuals) were found in 57.10% of patients with
goitre, 56.30% patients having autoimmune diseases and in
62.50% thyroid carcinoma patients. While levels of IFN-
α>4.00ng/ml (maximum level in healthy individuals) were
observed in only 14.30% patients with goitre, 6.30% patients
with autoimmune diseases and in 18.80% thyroid carcinoma
patients.
The incidence of thyroid carcinoma patients having
higher levels of IL-8 as compared to that of healthy indi-
viduals increased with the increase in disease stage. That is,
40% of early-stage thyroid carcinoma patients as compared
to 82.40% advanced-stage thyroid carcinoma patients had
higher IL-8 levels than the maximum range found in healthy
individuals.
Association of the serum IL-8 and IFN-α levels with
diﬀerent clinicopathological parameters have been studied
by Mann-Whitney U test. It revealed that elevated serum IL-
8 levels were signiﬁcantly associated with advanced-disease
stage (Figure 3). In fact, serum IL-8 levels were signiﬁcantly
increased in patients with advanced stage compared to those
with early-stage disease (445.12 ± 214.30 versus 101.56 ±
53.89; P = .016).
Moreover, Spearman rank’s correlation analysis revealed
signiﬁcant positive relationships between IL-8 levels and
disease stage (r = 0.437, P = .012). IFN-α levels were not
signiﬁcantly associated nor did they exhibit any signiﬁcant
relationship with any of the clinicopathological parameters.
Yi Ren et al. demonstrated that high serum IL-8 level cor-
related with large tumor volume and advanced tumor stage
in patients with hepatocellular carcinoma [37]. Increased
IL-8 expression has been found in various tumors and in
some studies IL-8 serum and/or tissue levels correlate with6 Journal of Thyroid Research
Table 2: Clinicopathological parameters of thyroid cancer patients.
Parameters N (%) Parameters N (%)
Age Multifocality
<45 years 17 (53.10) Present 14 (43.70)
≥45 years 15 (46.90) Absent 18 (56.30)
Gender Bilaterality
Male 09 (28.10) Unilateral 23 (71.90)
Female 23 (71.90) Bilateral 09 (28.10)
Tumor size Haemorrhagic area
T1 + T2 16 (50.00) Present 07 (21.90)
T3 + T4 16 (50.00) Absent 25 (78.10)
Lymph node metastasis Necrosis
Present 18 (56.30) Present 03 (9.40)
Absent 14 (43.70) Absent 29 (90.60)
Distant metastasis Calciﬁcation
Present 21 (65.60) Present 19 (59.40)
Absent 11 (34.30) Absent 13 (40.60)
Stage Sclerosis
Early stage (Stage I & II) 15 (46.90) Present 04 (12.50)
Advanced stage (Stage III & IV) 17 (53.10) Absent 28 (87.50)
Lymphatic permeation Extrathyroidal extension
Present 04 (12.50) Present 13 (40.60)
Absent 28 (87.50) Absent 19 (59.40)
Vascular permeation Fibrosis
Present 08 (25.00) Present 08 (25.00)
Absent 24 (75.00) Absent 24 (75.00)
Capsular invasion Inﬂammation
Present 13 (40.60) Present 14 (43.70)
Absent 19 (59.40) Absent 18 (56.30)
Encapsulation Diﬀerentiation
Well-encapsulated 27 (84.40) Well 22 (68.75)
Not encapsulated 05 (15.60) Moderate/Poor 10 (31.25)
Table 3: Signiﬁcance of IL-8 levels in patients with thyroid diseases as compared to healthy individuals.
Subjects Mean ± S.E (pg/ml) Median Minimum Maximum P value
Healthy individuals 3.15 ± 0.58 2.97 0.00 7.00
Total patients 231.67 ± 72.51 .001
Goitre 187.16 ± 93.88 8.41 0.00 1899.06 .002
Autoimmune disorders 185.30 ± 167.84 7.92 0.00 2700.00 .034
Graves’ disease 20.21 ± 10.93 .085
Hashimoto disorder 680.57 ± 673.14 .097
Thyroid Carcinoma 284.08 ± 118.97 69.35 0.00 3200.00 .001
Papillary carcinoma 116.34 ± 44.36 .006
Follicular carcinoma 514.13 ± 295.64 .030
Medullary carcinoma 828.96 ± 790.79 .456
Anaplastic carcinoma 27.17 ± 19.50 .003
Early stage (Stage I & II) 101.56 ± 53.89 .286
Advanced stage (Stage III & IV) 445.12 ± 214.30 <.001Journal of Thyroid Research 7
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Figure 2: (a) Incidence of IL-8 and IFN-α levels in patients with thyroid diseases as compared to healthy individuals. (b) Incidence of IL-8
and IFN-α levels in thyroid carcinoma patients as compared to healthy individuals. (c) Incidence of IL-8 and IFN-α levels in early- and
advanced-stage thyroid carcinoma patients as compared to healthy individuals.
Table 4: Signiﬁcance of IFN-α levels in patients with thyroid diseases as compared to healthy individuals.
Subjects Mean ± S.E (IU/ml) Median Minimum Maximum P value
Healthy individuals 2.41 ± 0.18 2.26 0.50 4.00
Total patients 3.82 ± 0.50 .002
Goitre 3.40 ± 0.30 3.14 2.27 9.07 .001
Autoimmune disorders 2.97 ± 0.12 3.02 2.01 4.16 .009
Graves’ disease 2.91 ± 0.15 .028
Hashimoto disorder 3.14 ± 0.21 .054
Thyroid carcinoma 4.51 ± 1.06 3.21 2.14 36.67 <.001
Papillary carcinoma 5.10 ± 1.87 .003
Follicular carcinoma 3.48 ± 0.31 .007
Medullary carcinoma 4.72 ± 1.29 .006
Anaplastic carcinoma 3.10 ± 0.27 .087
Early stage (Stage I & II) 5.37 ± 2.24 .007
Advanced stage (Stage III & IV) 3.76 ± 0.36 <.0018 Journal of Thyroid Research
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tumor progression and metastasis [42–45]. So, this ﬁnding
additionally supports the role of IL-8 in the progression of
thyroid carcinoma.
The relative risk study indicated that 14/17 advanced-
stagethyroidcarcinomapatientsand6/15early-stagethyroid
carcinoma patients had elevated IL-8 levels (>7.00pg/ml)
(Figure 4), which indicates IL-8 as a risk factor in develop-
ment of advanced-stage thyroid cancer.
4. Conclusion
Finally concluding, as both serum IL-8 and IFN-α levels
were signiﬁcantly higher, not only in thyroid cancer patients,
but also in patients having goitre and autoimmune diseases,
they can be used for diﬀerentiating such patients, having any
disease of thyroid gland, from that of healthy individuals.
Since such conditions often constitute prevalent pre-existing
disease states in the pathogenesis of thyroid cancer, these
resultsstronglysuggestanassociationbetweenIL-8andIFN-
α upregulation and development of thyroid carcinoma.
Moreover, IL-8 could eﬃciently discriminate between
early- and advanced-stage disease. Also, the major ﬁndings
demonstrate that IL-8 levels, were signiﬁcantly positively
related to the disease stage and the elevated IL-8 levels were
predominantly associated with the advanced stage of the
disease whereas IFN-α levels did not show any signiﬁcant
correlation or association with any of the histopathologi-
cal parameters of thyroid carcinoma patients. Thus, IL-8
seems to have a role in thyroid cancer pathogenesis, and
measurement of preoperative serum IL-8 levels might be
more useful and feasible in the clinical setting to predict
tumor stage where it may represent a putative target for
innovative diagnostic and therapeutic strategies. However,
further studies including more number of patients and
evaluating the postoperative changes in serum IL-8 levels
mayprovideadditionalpredictivevalueontumorrecurrence
and prognosis.
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